Ignite Creation Date:
2024-05-06 @ 7:20 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05973591
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-03
First Post:
2023-07-16
Brief Title:
The Impact of Ivabradine on Left Ventricular Reverse Remodeling in Nonischemic Dilated Cardiomyopathy NIDCM on Current Medical Therapy Era
Sponsor:
Yonsei University
Organization:
Yonsei University
Study Overview
Official Title:
The Impact of Ivabradine on Left Ventricular Reverse Remodeling in Nonischemic Dilated Cardiomyopathy NIDCM on Current Medical Therapy Era
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In non-ischemic dilated cardiomyopathy NIDCM left ventricular reverse remodeling LVRR can be achieved through guideline-directed medical therapy GDMT LVRR is defined as an increase in left ventricular ejection fraction LVEF of more than 10 in heart failure patients with a baseline LVEF of 40 or less or an increase in LVEF of more than 40 at follow-up which is classified as heart failure with improved EF HFimpEF according to current guidelines Several studies have examined the prevalence and predictors of LVRR in NIDCM However there is a lack of research on LVRR in the context of contemporary pharmacotherapy Studies have demonstrated the beneficial effects of ivabradine in heart failure with reduced ejection fraction HFrEF improving patients prognosis A sub-study of the SHIFT trial indicated that ivabradine may also contribute to cardiac remodeling reversal in patients with HFrEF However there is limited evidence exploring the relationship between ivabradine and LVRR particularly in the context of NIDCM
Consequently this study is a retrospective multi-center cohort study aiming to evaluate the impact of ivabradine on LVRR in patients with NIDCM in the current era of medical therapy Furthermore by conducting this study we aim to gain insights into the potential role of ivabradine in promoting LVRR in NIDCM patients receiving contemporary drug therapy
Consequently this study is a retrospective multi-center cohort study aiming to evaluate the impact of ivabradine on LVRR in patients with NIDCM in the current era of medical therapy Furthermore by conducting this study we aim to gain insights into the potential role of ivabradine in promoting LVRR in NIDCM patients receiving contemporary drug therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None